Abstract | PURPOSE: We report the role of relative lymphocyte count (RLC) as a potential biomarker with prognostic impact for catumaxomab efficacy and overall survival (OS) based on a post hoc analysis of the pivotal phase II/III study of intraperitoneal catumaxomab treatment of malignant ascites. EXPERIMENTAL DESIGN: The impact of treatment and RLC on OS was evaluated using multivariate Cox models. Kaplan-Meier and log-rank tests were used for group comparisons. Survival analyses were performed on the safety population [patients with paracentesis plus ≥ 1 dose of catumaxomab (n = 157) and paracentesis alone (n = 88)]. Determination of the optimal cutoff value for RLC was based on five optimality criteria. RESULTS: OS was significantly longer with catumaxomab versus paracentesis alone (P = 0.0219). The 6-month OS rate with catumaxomab was 28.9% versus 6.7% with paracentesis alone. RLC had a positive impact on OS and was an independent prognostic factor (P < 0.0001). In patients with RLC > 13% (n = 159: catumaxomab, 100 and control, 59), catumaxomab was associated with a favorable effect on OS versus paracentesis alone (P = 0.0072), with a median/mean OS benefit of 41/131 days and an increased 6-month survival rate of 37.0% versus 5.2%, respectively. In patients with RLC ≤ 13% at screening (n = 74: catumaxomab, 50 and control, 24), the median (mean) OS difference between the catumaxomab and the control group was 3 (16) days, respectively (P = 0.2561). CONCLUSIONS: OS was significantly improved after catumaxomab treatment in patients with malignant ascites. An RLC > 13% at baseline was a significant prognostic biomarker.
|
Authors | Markus M Heiss, Michael A Ströhlein, Carsten Bokemeyer, Dirk Arnold, Simon L Parsons, Diane Seimetz, Horst Lindhofer, Elisabeth Schulze, Michael Hennig |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 20
Issue 12
Pg. 3348-57
(Jun 15 2014)
ISSN: 1557-3265 [Electronic] United States |
PMID | 24714773
(Publication Type: Clinical Trial, Phase II, Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | ©2014 American Association for Cancer Research. |
Chemical References |
- Antibodies, Bispecific
- Biomarkers
- catumaxomab
|
Topics |
- Antibodies, Bispecific
(therapeutic use)
- Ascites
(blood, drug therapy, mortality, pathology)
- Biomarkers
(analysis)
- Case-Control Studies
- Follow-Up Studies
- Humans
- Injections, Intraperitoneal
- Lymphocyte Count
- Neoplasm Staging
- Paracentesis
(mortality)
- Prognosis
- Survival Rate
|